Brainstorm Cell Therapeutics (BCLI) Tops Q3 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
BrainStorm Cell Therapeutics Reports Third Quarter 2015 Financial Results And Provides Corporate Update
November 17, 2015 7:00 AM ESTHACKENSACK, N.J. and PETACH TIKVAH, Israel, Nov. 17, 2015 /PRNewswire/ --Â BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced financial results and provided a business update for the third quarter ended September 30, 2015.
"2015 continues to be a year of important advances in our clinical and corporate programs," stated BrainStorm's CEO, Chaim Lebovits. "Specifically, we are making significant progress in the ongoing development program of our lead development candidate,... More
